These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 135588)

  • 1. Mechanisms involved in enhancement of plasma fibrinolytic activity by chloroform.
    Moroz LA; Gilmore NJ
    Blood; 1976 Nov; 48(5):777-90. PubMed ID: 135588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolysis in normal plasma and blood: evidence for significant mechanisms independent of the plasminogen-plasmin system.
    Moroz LA; Gilmore NJ
    Blood; 1976 Oct; 48(4):531-45. PubMed ID: 134751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
    Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
    J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mafenide (Sulfamylon) inhibits plasmin fibrinolytic activity.
    Weisdorf DJ; Aldridge JH
    Thromb Haemost; 1988 Jun; 59(3):440-4. PubMed ID: 2973151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of plasminogen activation by the plasmin-staphylokinase complex in plasma of alpha2-antiplasmin-deficient mice.
    Okada K; Ueshima S; Tanaka M; Fukao H; Matsuo O
    Blood Coagul Fibrinolysis; 2000 Oct; 11(7):645-55. PubMed ID: 11085285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The fibrinolytic system in man.
    Collen D; Lijnen HR
    Crit Rev Oncol Hematol; 1986; 4(3):249-301. PubMed ID: 2420482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staphylokinase reduces plasmin formation by endogenous plasminogen activators.
    Jin T; Bokarewa M; Zhu Y; Tarkowski A
    Eur J Haematol; 2008 Jul; 81(1):8-17. PubMed ID: 18331597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
    Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
    Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
    Duboscq C; Genoud V; Parborell MF; Kordich LC
    Thromb Res; 1997 Jun; 86(6):505-13. PubMed ID: 9219330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An anti-plasminogen antibody preparation that inhibits the activation of human plasminogen but enhances the activator activity of the B-chain-streptokinase complex.
    Summaria L; Pavlovic B; Sandesara J
    Thromb Res; 1989 Apr; 54(1):1-15. PubMed ID: 2727955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for studying fibrinolytic pathway components in human plasma.
    Wohl RC; Sinio L; Robbins KC
    Thromb Res; 1982 Sep; 27(5):523-35. PubMed ID: 6217585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiology of plasminogen: with special reference to activation and degradation.
    Takada A; Takada Y
    Haemostasis; 1988; 18 Suppl 1():25-35. PubMed ID: 3280423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmin activity is required for myogenesis in vitro and skeletal muscle regeneration in vivo.
    Suelves M; López-Alemany R; Lluís F; Aniorte G; Serrano E; Parra M; Carmeliet P; Muñoz-Cánoves P
    Blood; 2002 Apr; 99(8):2835-44. PubMed ID: 11929773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The enhancement of chloroform-induced plasma proteolytic activity by epsilon aminocaproic acid.
    DONALDSON VH; RATNOFF OD
    J Exp Med; 1962 Apr; 115(4):695-706. PubMed ID: 13887179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of heparin on the proteolytic and fibrinolytic activity on plasmin(ogen) and fibrin clot lysis].
    Kudinov SA; Kolesnik LA; Makogonenko EM; Shuliakovskaia TA
    Biokhimiia; 1989 Nov; 54(11):1881-7. PubMed ID: 2534055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies inhibitory to human plasmin. Definitive demonstration of a role for plasmin in activating the proenzyme of urokinase-type plasminogen activator.
    Sim PS; Fayle DR; Doe WF; Stephens RW
    Eur J Biochem; 1986 Aug; 158(3):537-42. PubMed ID: 2942403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.